| Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. | |
| | |
MedLine Citation:
|
PMID: 12670887 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Using a tissue microarray cohort of 300 breast cancers and 84 samples of normal breast epithelium, we analyzed HER2/neu expression and compared traditional clinical (manual) scoring with a recently developed system for the quantitative measurement of immunohistochemical stains (AQUA). As expected, both methods identified a population (10-15%) of high-HER2-expressing tumors with poor 30-year disease-related survival. Using AQUA analysis, we found that normal epithelium expresses a low but detectable level of HER2 and that 17.5% of tumors exhibit similar low-level HER2 expression. This low group was not definable by manual scoring. Surprisingly, HER2-normal tumors were as aggressive as HER2-overexpressing tumors. Our studies suggest that in situ quantitative measurement of HER2 stratifies breast tumors into three expression levels: normal, intermediate, and high, where both normal and high levels are associated with a worse outcome. |
| | |
Authors:
|
Robert L Camp; Marisa Dolled-Filhart; Bonnie L King; David L Rimm |
Related Documents
:
|
6094037 - Tissue proteins in breast cancer, as studied by use of two-dimensional electrophoresis. 23301497 - Size-dependent tumor penetration and in vivo efficacy of monodisperse drug-silica nanoc... 1252327 - Oestradiol synthesis from c19 steroids by human breast cancers. 6975467 - Detection of placental protein five (pp5) and pregnancy-specific glycoprotein (sp1) in ... 23397427 - Analysis of metallothionein and vimentin immunoreactivity in pharyngeal squamous cell c... 17036057 - Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger ... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Cancer research Volume: 63 ISSN: 0008-5472 ISO Abbreviation: Cancer Res. Publication Date: 2003 Apr |
Date Detail:
|
Created Date: 2003-04-02 Completed Date: 2003-04-22 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 2984705R Medline TA: Cancer Res Country: United States |
Other Details:
|
Languages: eng Pagination: 1445-8 Citation Subset: IM |
Affiliation:
|
Department of Pathology, Yale University, School of Medicine, New Haven, Connecticut 06520, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Breast
/
metabolism Breast Neoplasms / metabolism*, pathology Cohort Studies Epithelium / metabolism Humans Immunohistochemistry Lymphatic Metastasis Multivariate Analysis Prognosis Receptor, erbB-2 / biosynthesis* |
| Grant Support | |
ID/Acronym/Agency:
|
K0-8 ES11571/ES/NIEHS NIH HHS; R0-1 GM57604/GM/NIGMS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
EC 2.7.10.1/Receptor, erbB-2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ.
Next Document: Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method...